Literature DB >> 18843288

Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy.

Y-Y Hwang, W W W Cheung, A Y H Leung, E Tse, W-Y Au, Y-L Kwong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18843288     DOI： 10.1038/leu.2008.282

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

Review 1.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

2.  The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

Authors:  Jew Win Kuan; Kian Meng Chang; Ngee Siang Lau; Purushothaman Visalachy; Sen Mui Tan; Tee Chuan Ong; Anselm Ting Su
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

Review 3.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.